1. Otezla (apremilast), manufactured by Summit, N.J.-based Celgene Corp., has been approved as a treatment for psoriatic arthritis in adults.
2. Xolair (omalizumab), co-developed and co-promoted by San Francisco-based Genentech and East Hanover, N.J.-based Novartis, has been approved to treat a chronic form of hives.
3. The FDA has approved Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) to be used as a preventative measure against potential pulmonary embolism-causing blood clots for patients who have undergone hip or knee replacement therapy.
4. The FDA has approved Myalept, metreleptin for injection, as a treatment option for patients with congenital generalized or acquired generalized lipodystrophy, a condition where patients have little to no fat tissue.
More Articles on Pharmaceuticals:
Pacira Joins NPSF Coalition
OxyContin Manufacturer Creates Tamper-Resistant Hydrocodone Drug
New Drugs Funneled $4B Into Exchange-Traded Funds in 2014
